Add to ORKGThe article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy for mCRC treatment. The meeting was conducted during the 11th ESMO/World Gastrointestinal Cancer Congress (WGICC) in Barcelona in June 2009. The manuscript describes the outcome of an expert discussion leading to an expert recommendation. The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC.status: publishe
Over the past two decades, the treatment outcomes in metastatic colorectal cancer (mCRC) have been r...
Over 1.8 million new colorectal cancer cases and 881,000 deaths are estimated to occur in 2018. Deat...
The achievements in the treatment of metastatic colorectal cancer during recent years are based on a...
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common ca...
The therapeutic landscape of metastatic colorectal cancer (mCRC) has changed substantially with the ...
Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therap...
The medical treatment of patients with metastatic colorectal cancer (mCRC) has evolved greatly in th...
Treatment options for colorectal cancer have increased substantially in the past decade, with the in...
Contains fulltext : 165965.pdf (publisher's version ) (Closed access)Colorectal ca...
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 2...
More therapeutic options are now available than ever before for patients with metastatic colorectal ...
Characterization of molecular and cellular alterations in-volved in the initiation and progression o...
Colorectal cancer is the 2nd cause of cancer related death in industrialised countries. 20% of all p...
The treatment of metastatic colorectal cancer has evolved greatly in the last 15 years, involving co...
Colorectal cancer remains one of the most frequently diagnosed cancers in the developed world. The a...
Over the past two decades, the treatment outcomes in metastatic colorectal cancer (mCRC) have been r...
Over 1.8 million new colorectal cancer cases and 881,000 deaths are estimated to occur in 2018. Deat...
The achievements in the treatment of metastatic colorectal cancer during recent years are based on a...
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common ca...
The therapeutic landscape of metastatic colorectal cancer (mCRC) has changed substantially with the ...
Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therap...
The medical treatment of patients with metastatic colorectal cancer (mCRC) has evolved greatly in th...
Treatment options for colorectal cancer have increased substantially in the past decade, with the in...
Contains fulltext : 165965.pdf (publisher's version ) (Closed access)Colorectal ca...
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 2...
More therapeutic options are now available than ever before for patients with metastatic colorectal ...
Characterization of molecular and cellular alterations in-volved in the initiation and progression o...
Colorectal cancer is the 2nd cause of cancer related death in industrialised countries. 20% of all p...
The treatment of metastatic colorectal cancer has evolved greatly in the last 15 years, involving co...
Colorectal cancer remains one of the most frequently diagnosed cancers in the developed world. The a...
Over the past two decades, the treatment outcomes in metastatic colorectal cancer (mCRC) have been r...
Over 1.8 million new colorectal cancer cases and 881,000 deaths are estimated to occur in 2018. Deat...
The achievements in the treatment of metastatic colorectal cancer during recent years are based on a...